British regulators approved GlaxoSmithKline drug sotrovimab to treat those at high risk of developing severe symptoms.
Regulators in the United Kingdom have given the green light for the use of a monoclonal therapy, called sotrovimab, to treat those at high risk of developing severe COVID-19 symptoms, with the drug’s manufacturer GlaxoSmithKline saying it “retains activity” against the new Omicron variant.
The news came as South Korea’s daily coronavirus case numbers rose to a new high with authorities halting quarantine exemptions for fully vaccinated inbound travellers for two weeks in a bid to fend off the new variant.
Meanwhile in the United States, fears over the impact of the new coronavirus strain have risen after it reported its first case in a fully vaccinated person in California. The case returned from South Africa on November 22 and tested positive seven days later.
In South Africa, where scientists detected the omicron variant last week, new infections doubled in a day signaling a dramatic surge in the country.